Cefazolin, also known as cefazoline and cephazolin, is a first-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections.[2] Specifically it is used to treat cellulitis, urinary tract infections, pneumonia, endocarditis, joint infection, and biliary tract infections.[2] It is also used to prevent group B streptococcal disease around the time of delivery and before surgery.[2] It is typically given by injection into a muscle or vein.[2]

Cefazolin
Clinical data
Pronunciation/səˈfæzələn/[1]
Trade namesAncef, Cefacidal, other
AHFS/Drugs.comMonograph
Pregnancy
category
  • AU: B1
Routes of
administration
intravenous, intramuscular
Drug classFirst-generation cephalosporin
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
BioavailabilityNA
Metabolism?
Elimination half-life1.8 hours (given IV)
2 hours (given IM)
Excretionkidney, unchanged
Identifiers
  • (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.043.042 Edit this at Wikidata
Chemical and physical data
FormulaC14H14N8O4S3
Molar mass454.50 g·mol−1
3D model (JSmol)
Melting point198 to 200 °C (388 to 392 °F) (decompose.)
  • O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)Cn3nnnc3)CSc4nnc(s4)C)C(=O)O
  • InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1 checkY
  • Key:MLYYVTUWGNIJIB-BXKDBHETSA-N checkY
  (verify)

Common side effects include diarrhea, vomiting, yeast infections, and allergic reactions.[2] Historically, it was thought to be contraindicated in patients with allergies to penicillin, although several recent studies have refuted this and it is proven to be safe in almost all patients, including those with known penicillin allergies.[3] It is relatively safe for use during pregnancy and breastfeeding.[2][4] Cefazolin is in the first-generation cephalosporin class of medication and works by interfering with the bacteria's cell wall.[2]

Cefazolin was patented in 1967 and came into commercial use in 1971.[5][6] It is on the World Health Organization's List of Essential Medicines.[7] It is available as a generic medication.[2]

Medical uses

edit

Cefazolin is used in a variety of infections provided that susceptible organisms are involved. It is indicated for use in the following infections:[8]

It can also be used peri-operatively to prevent infections post-surgery, and is often the preferred drug for surgical prophylaxis.[8]

There is no penetration into the central nervous system and therefore cefazolin is not effective in treating meningitis.[9]

Cefazolin has been shown to be effective in treating methicillin-susceptible Staphylococcus aureus (MSSA) but does not work in cases of methicillin-resistant Staphylococcus aureus (MRSA).[8] In many instances of staphylococcal infections, such as bacteremia, cefazolin is an alternative to penicillin in patients who are allergic to penicillin.[9] However, there is still potential for a reaction to occur with cefazolin and other cephalosporins in patients allergic to penicillin.[8] Resistance to cefazolin is seen in several species of bacteria, such as Mycoplasma and Chlamydia, in which case different generations of cephalosporins may be more effective.[10] Cefazolin does not fight against Enterococcus, anaerobic bacteria, or atypical bacteria, among others.[9]

Bacterial susceptibility

edit

As a first-generation cephalosporin antibiotic, cefazolin and other first-generation antibiotics are very active against gram-positive bacteria and some gram-negative bacteria.[8] Their broad spectrum of activity can be attributed to their improved stability to many bacterial beta-lactamases compared to penicillins.[9]

Spectrum of activity

edit

Gram-positive aerobes:[8][9]

Gram-Negative Aerobes:[11]

Non susceptible

edit

The following are not susceptible:[8][9]

Special populations

edit

Pregnancy

edit

Cefazolin is pregnancy category B, indicating general safety for use in pregnancy. Caution should be used in breastfeeding as a small amount of cefazolin enters the breast milk.[8] Cefazolin can be used prophylactically against perinatal Group B streptococcal infection (GBS). Although penicillin and ampicillin are the standard of care for GBS prophylaxis, penicillin-allergic women with no history of anaphylaxis can be given cefazolin instead. These patients should be closely monitored as there is a small chance of an allergic reaction due to the similar structure of the antibiotics.[12]

Newborns

edit

There has been no established safety and effectiveness for use in premature infants and neonates.[8]

Elderly

edit

No overall differences in safety or effectiveness were observed in clinical trials comparing elderly and younger subjects, however the trials could not eliminate the possibility that some older individuals may have a higher level of sensitivity.[8]

Additional considerations

edit

People with kidney disease and those on hemodialysis may need the dose adjusted.[8] Cefazolin levels are not significantly affected by liver disease.

As with other antibiotics, cefazolin may interact with other medications being taken. Some important drugs that may interact with cefazolin such as probenecid.[9]

Side effects

edit

Side effects associated with use of cefazolin therapy include:[8]

  • Common (1–10%): diarrhea, stomach pain or upset stomach, vomiting, and rash.
  • Uncommon (<1%): dizziness, headache, fatigue, itching, transient hepatitis.[13]

Patients with penicillin allergies could experience a potential reaction to cefazolin and other cephalosporins.[8] As with other antibiotics, patients experiencing watery and/or bloody stools occurring up to three months following therapy should contact their prescriber.[8]

Like those of several other cephalosporins, the chemical structure of cefazolin contains an N-methylthiodiazole (NMTD or 1-MTD) side-chain. As the antibiotic is broken down in the body, it releases free NMTD, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase) and a reaction with ethanol similar to that produced by disulfiram (Antabuse), due to inhibition of aldehyde dehydrogenase.[14] Those with an allergy to penicillin may develop a cross sensitivity to cefazolin.[15][16]

Mechanism of action

edit

Cefazolin inhibits cell wall biosynthesis by binding penicillin-binding proteins which stops peptidoglycan synthesis. Penicillin-binding proteins are bacterial proteins that help to catalyze the last stages of peptidoglycan synthesis, which is needed to maintain the cell wall. They remove the D-alanine from the precursor of the peptidoglycan. The lack of synthesis causes the bacteria to lyse because they also continually break down their cell walls. Cefazolin is bactericidal, meaning it kills the bacteria rather than inhibiting their growth.[9]

Cost

edit

Cefazolin is relatively inexpensive.[17]

Trade names

edit

It was initially marketed by GlaxoSmithKline under the trade name Nostof.[18]

Other trade names include: Cefacidal, Cefamezin, Cefrina, Elzogram, Faxilen, Gramaxin, Kefol, Kefzol, Kefzolan, Kezolin, Novaporin, Reflin, Zinol, and Zolicef.

References

edit
  1. ^ "Cefazolin". Merriam-Webster.com Dictionary. Merriam-Webster. Retrieved 2016-01-21.
  2. ^ a b c d e f g h "Cefazolin Sodium". The American Society of Health-System Pharmacists. Retrieved 8 December 2016.
  3. ^ "NEJM Journal Watch: Summaries of and commentary on original medical and scientific articles from key medical journals". www.jwatch.org. Retrieved 2023-01-20.
  4. ^ Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 84. ISBN 9781284057560.
  5. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 493. ISBN 9783527607495. Archived from the original on 2017-09-10.
  6. ^ US patent 3516997, Takano T, Kurita M, Nikaido H, Mera M, Konishi N, Nakagawa R, "3,7-disubstituted cephalosporin compounds and preparation thereo", published 1970-06-23, issued 1970-06-23, assigned to Fujisawa Pharmaceutical Co Ltd 
  7. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. ^ a b c d e f g h i j k l m n "DailyMed - CEFAZOLIN - cefazolin sodium injection, powder, for solution". dailymed.nlm.nih.gov. Archived from the original on 2016-03-06. Retrieved 2015-11-05.
  9. ^ a b c d e f g h Trevor AJ, Katzung BG, Masters S (2015). Basic & Clinical Pharmacology. New York: McGraw Hill Education. pp. 776–778. ISBN 978-0-07-182505-4.
  10. ^ "Cefazolin (Injection Route)". Mayo Clinic. 1 July 2015. Archived from the original on 19 April 2014.
  11. ^ Beauduy C, Winston L (2021). Basic & Clinical Pharmacology (15 ed.). McGraw Hill.
  12. ^ "Prevention of Perinatal Group B Streptococcal Disease". www.cdc.gov. Archived from the original on 2015-11-15. Retrieved 2015-11-05.
  13. ^ "Cefazolin Prescribing Information" (PDF). FDA. 2004. Archived (PDF) from the original on 2016-03-04.
  14. ^ Stork CM (2006). Antibiotics, antifungals, and antivirals. New York: McGraw-Hill. p. 847.
  15. ^ "Pharmaceutical Sciences CSU Parenteral Antibiotic Allergy cross-sensitivity chart" (PDF). Vancouver Acute Pharmaceutical Sciences, Vancouver Hospital & Health Sciences Centre. 2016. Archived (PDF) from the original on April 17, 2016. Retrieved May 19, 2017.
  16. ^ Gonzalez-Estrada A, Radojicic C (May 2015). "Penicillin allergy: A practical guide for clinicians". Cleveland Clinic Journal of Medicine. 82 (5): 295–300. doi:10.3949/ccjm.82a.14111. PMID 25973877. S2CID 6717270.
  17. ^ Cunha BA (2009). Infectious Diseases in Critical Care Medicine. CRC Press. p. 506. ISBN 978-1-4200-9241-7.
  18. ^ "Cefazolin Sodium Injection". MedlinePlus Drug Information. U.S. National Library of Medicine. Archived from the original on 2015-10-06. Retrieved 2015-11-05.
edit